about
Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancerStudy of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer.Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer.Further study of circulating IgG antibodies to CD25-derived peptide antigens in nonsmall cell lung cancerEffect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy.IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.FDG Pulmonary Uptake Changes During and Postradiotherapy Compared to Pretreatment in Predicting Radiation-induced Lung Toxicity in Non-Small Cell Lung Cancer.Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer[Small cell lung carcinoma metastatic to the ovary: reports of two cases]Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancerA framework for modeling radiation induced lymphopenia in radiotherapyDoses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancerA Validation Study on IDO Immune Biomarkers for Survival Prediction in Non-Small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early-Stage DiseaseMachine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non-Small Cell Lung Cancer
P50
Q34937327-302DA68C-27E4-43CE-8D88-C159D1AE19E1Q36146042-5833FF69-DBE1-4D58-A301-4E9F27546136Q36433810-AD4CE00A-D282-4CA9-BE37-8123AE7F4C45Q36694379-CDAB6FEE-A1AA-4B92-B28F-533A5A32584DQ38376135-3B0049AD-62A1-409C-A446-6D1AF433CC40Q42362026-83D6DE5D-6679-48CF-A8DC-4E40DB4B7BEBQ50103704-A0235071-9E75-488B-9295-924389AE8A76Q50618634-78D1B22C-756C-44FC-A37B-EAE9E0CF16E1Q54281576-7F4F9955-75BA-4764-BF66-9A75944CD89EQ54382756-BCE223DE-54D0-41CC-B1D0-3B51218824D0Q58594704-79D9AB51-3D5C-42FF-AFA1-5F9A0FA0831BQ82893773-F579D615-13E4-44E0-A735-1027DE98DCB1Q86521367-3B814CF5-8392-456C-9FB2-0A2B994B0748Q91641619-E20ED275-0A2D-4E9B-9D3A-0DD3792A826BQ92984857-F3BE2C52-ED8A-4D3F-B9A1-8EFCC6640258Q93021155-307E6539-7058-4FC1-B355-8F27801D6BFFQ93137232-1D3D92D7-0F0A-40EE-B30F-16559CDB740D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Weili WANG
@en
Weili WANG
@nl
type
label
Weili WANG
@en
Weili WANG
@nl
prefLabel
Weili WANG
@en
Weili WANG
@nl
P31
P496
0000-0002-1627-3025